Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Перспективы применения метабиотиков в комплексной терапии заболеваний кишечника
Перспективы применения метабиотиков в комплексной терапии заболеваний кишечника
Трухманов А.С., Румянцева Д.Е. Перспективы применения метабиотиков в комплексной терапии заболеваний кишечника. Consilium Medicum. 2020; 22 (8): 51–56. DOI: 10.26442/20751753.2020.8.200282
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Представить современные данные о роли микробиоты в развитии заболеваний кишечника, рассмотреть методы ее поддержания и коррекции.
Основные положения. Микробиота человека играет важную роль в поддержании гомеостаза и развитии заболеваний, принимая участие в воспалительных сигнальных путях, метаболических процессах, пищеварении, регуляции клеточного и гуморального иммунного ответа, моторики желудочно-кишечного тракта. Результаты проведенных исследований демонстрируют изменение микробиоты у пациентов с патологией кишечника. В этом свете актуальной представляется коррекция микробиоты с помощью метабиотиков в целях повышения эффективности терапии у больных с синдромом раздраженного кишечника, воспалительными заболеваниями кишечника, острыми кишечными инфекциями.
Заключение. Включение метабиотиков в состав комплексной терапии заболеваний кишечника повышает ее эффективность. Требуется дальнейшее изучение возможностей коррекции и/или поддержания нормального состава микробиоты с помощью метабиотиков, их воздействия на патогенетические звенья синдрома раздраженного кишечника, воспалительных заболеваний кишечника.
Ключевые слова: микробиота, метабиотики, синдром раздраженной кишки, воспалительные заболевания кишечника, болезнь Крона, язвенный колит.
Key points. The human microbiota plays an important role in maintaining homeostasis and the development of diseases, taking part in inflammatory signaling pathways, metabolic processes, digestion, regulation of the cellular and humoral immune response and gastrointestinal motility. The results of these studies demonstrate changes in the microbiota in patients with intestinal pathology. In this light, it seems relevant to correct the microbiota using metabiotics in order to increase the effectiveness of therapy in patients with irritable bowel syndrome, inflammatory bowel diseases, and acute intestinal infections.
Conclusion. The inclusion of metabiotics in the complex therapy of intestinal diseases increases its effectiveness. Further study of the possibilities of correcting and/or maintaining the normal composition of microbiota using metabiotics as well as their effect on the pathogenetic links of irritable bowel syndrome, inflammatory bowel diseases is required.
Key words: microbiota, metabiotics, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis.
Основные положения. Микробиота человека играет важную роль в поддержании гомеостаза и развитии заболеваний, принимая участие в воспалительных сигнальных путях, метаболических процессах, пищеварении, регуляции клеточного и гуморального иммунного ответа, моторики желудочно-кишечного тракта. Результаты проведенных исследований демонстрируют изменение микробиоты у пациентов с патологией кишечника. В этом свете актуальной представляется коррекция микробиоты с помощью метабиотиков в целях повышения эффективности терапии у больных с синдромом раздраженного кишечника, воспалительными заболеваниями кишечника, острыми кишечными инфекциями.
Заключение. Включение метабиотиков в состав комплексной терапии заболеваний кишечника повышает ее эффективность. Требуется дальнейшее изучение возможностей коррекции и/или поддержания нормального состава микробиоты с помощью метабиотиков, их воздействия на патогенетические звенья синдрома раздраженного кишечника, воспалительных заболеваний кишечника.
Ключевые слова: микробиота, метабиотики, синдром раздраженной кишки, воспалительные заболевания кишечника, болезнь Крона, язвенный колит.
________________________________________________
Key points. The human microbiota plays an important role in maintaining homeostasis and the development of diseases, taking part in inflammatory signaling pathways, metabolic processes, digestion, regulation of the cellular and humoral immune response and gastrointestinal motility. The results of these studies demonstrate changes in the microbiota in patients with intestinal pathology. In this light, it seems relevant to correct the microbiota using metabiotics in order to increase the effectiveness of therapy in patients with irritable bowel syndrome, inflammatory bowel diseases, and acute intestinal infections.
Conclusion. The inclusion of metabiotics in the complex therapy of intestinal diseases increases its effectiveness. Further study of the possibilities of correcting and/or maintaining the normal composition of microbiota using metabiotics as well as their effect on the pathogenetic links of irritable bowel syndrome, inflammatory bowel diseases is required.
Key words: microbiota, metabiotics, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis.
Полный текст
Список литературы
1. Lozupone CA, Stombaugh JI, Gordon JI et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220–30.
2. Полуэктова Е.А., Ляшенко О.С., Шифрин О.С. и др. Современные методы изучения микрофлоры желудочно-кишечного тракта человека. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 24 (5): 85–91.
[Poluektova E.A., Liashenko O.S., Shifrin O.S. et al. Sovremennye metody izucheniia mikroflory zheludochno-kishechnogo trakta cheloveka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 24 (5): 85–91 (in Russian).]
3. Кардымон О.Л., Кудрявцева А.В. Молекулярно-генетические методы для исследования микробиома кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (4): 4–13.
[Kardymon O.L., Kudriavtseva A.V. Molekuliarno-geneticheskie metody dlia issledovaniia mikrobioma kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 4–13 (in Russian).]
4. Кучумова С.Ю., Полуэктова Е.А., Шептулин А.А., Ивашкин В.Т. Физиологическое значение кишечной микрофлоры. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2011; 21 (5): 17–27.
[Kuchumova S.Iu., Poluektova E.A., Sheptulin A.A., Ivashkin V.T. Fiziologicheskoe znachenie kishechnoi mikroflory. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2011; 21 (5): 17–27 (in Russian).]
5. Dominguez-Bello MG et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010; 107: 11971–5.
6. Bäckhed F et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015; 17: 690–703.
7. Dominguez-Bello MG et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med 2016; 22: 250–3.
8. Tamburini S, N Shen, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nature Medicine 2016; 22: 713–22.
9. Yatsunenko T et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222–7.
10. Shaw S, Blanchard J, Bernstein C. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2687–92.
11. Barbara G, Stanghellini V, Brandi G et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100: 2560–8.
12. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157: 121–41.
13. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016; 535: 75–84.
14. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016; 16: 341–52.
15. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 2017; 20 (2): 145–55.
16. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735–42.
17. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–12.
18. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015; 17: 565–76.
19. Мухина А.Ю. Взаимосвязь состояния микробиоты толстой кишки и функций нервной системы в условиях иммобилизационного стресса и применения производного тафтцина у крыс. Автореф. дис. … канд. мед. наук. К., 2019.
[Mukhina A.Iu. Vzaimosviaz' sostoianiia mikrobioty tolstoi kishki i funktsii nervnoi sistemy v usloviiakh immobilizatsionnogo stressa i primeneniia proizvodnogo tafttsina u krys. Avtoref. dis. … kand. med. nauk. K., 2019 (in Russian).]
20. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500–12.
21. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306–14.
22. Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From Cytokines to Toll-Like Receptors and Beyond – Current Knowledge and Future Research Needs in Irritable Bowel Syndrome. J Neurogastroenterol Motil 2010; 16 (4): 363–73.
23. Шендеров Б. А. Медицинская микробная экология и функциональное питание. Т. 2. Социально-экологические и клинические последствия дисбаланса микробной экологии человека и животных. М.: ГРАНТЪ, 1998.
[Shenderov B.A.Medical microbial ecology and functional nutrition. T. 2. Socio-ecological and clinical consequences of imbalance in the microbial ecology of humans and animals. Moscow: GRANT, 1998 (in Russian).]
24. Palmer C, Bik E, DiGiulio D et al. Development of the human infant intestinal microbiota. PloS Biol 2007; 5: e177.
25. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: How do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5: 569–73.
26. Xu J et al. Inaugural Article: Honor thy symbionts. Proc Natl Acad Sci USA 2003; 100: 10452–9.
27. Hooper LV, Wong MH, Thelin A et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881–4.
28. Cherbut C, Aube AC, Blottiere HM, et al. In vitro contractile effects of short chain fatty acids in the rat terminal ileum. Gut 1996; 38: 53–8.
29. Rondeau MP, Meltzer K, Michel KE, et al. Short chain fatty acids stimulate feline colonic smooth muscle contraction. J Feline Med Surg 2003; 5: 167–73.
30. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28 (2): 203–9.
31. Spiller R, Jenkins D, Thornley J et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000; 47: 804–11.
32. Guarino MP, Sessa R, Altomare A et al. Human colonic myogenic dysfunction induced by mucosal lipopolysaccharide translocation and oxidative stress. Dig Liver Dis 2013; 45: 1011–6.
33. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32 (3): 305–15.
34. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010; 16 (9): 1583–97.
35. Шульпекова Ю.О. Кишечный микробиом как особый орган. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 24 (6): 82–8.
[Shulpekova Yu.O. The gut microbiome as a special organ. Grew up. zhurn. gastroenterology, hepatology, coloproctology. 2014; 24 (6): 82-8 (in Russian).]
36. Eamonn M, Quigley M. Microflora Modulation of Motility. J Neurogastroenterol Motil 2011; 17 (2): 140–7.
37. Zhu L, Liu W, Alkhouri R et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics 2014; 46 (18): 679–86.
38. Акиньшина А.И., Смирнова Д.В., Загайнова А.В. и др. Перспективы использования методов коррекции микробиоты при терапии воспалительных заболеваний кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (2): 12–22.
[Akin'shina A.I., Smirnova D.V., Zagainova A.V. et al. Perspektivy ispol'zovaniia metodov korrektsii mikrobioty pri terapii vospalitel'nykh zabolevanii kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (2): 12–22 (in Russian).]
39. Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology 2017; 152 (2): 327–339.e4.
40. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Nat Acad Sci 2008; 105 (43): 16731–6.
41. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712–21.
42. Ивашкин В.Т., Зольникова О.Ю. Синдром раздраженного кишечника с позиций изменений микробиоты. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (1): 84–92.
[Ivashkin V.T., Zol'nikova O.Iu. Sindrom razdrazhennogo kishechnika s pozitsii izmenenii mikrobioty. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (1): 84–92 (in Russian).]
43. Шептулин А.А., Визе-Хрипунова М.А. Римские критерии синдрома раздраженного кишечника IV пересмотра: есть ли принципиальные изменения? Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (5): 99–103.
[Sheptulin A.A., Vize-Khripunova M.A. Rimskie kriterii sindroma razdrazhennogo kishechnika IV peresmotra: est' li printsipial'nye izmeneniia? Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (5): 99–103 (in Russian).]
44. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016; 19.
45. Thabane M, Kottachchi DT, Marshall JK. Systematic review and metaanalysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535–44.
46. Villarreal AA, Aberger FJ, Benrud R et al. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17–20.
47. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205–15.
48. Jeffery IB, O’Toole PW, Öhman L et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997–1006.
49. Rajilić-Stojanović M, Biagi E, Heilig HGHJ et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–801.
50. Jalanka-Tuovinen J, Salojärvi J, Salonen A et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014; 63: 1737–45.
51. Шульпекова Ю.О., Бабаева Г.Г., Русяев В.Ю. Патогенетическое обоснование лечебного воздействия на микробиоту при синдроме раздраженного кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (4): 7–14.
[Shul'pekova Iu.O., Babaeva G.G., Rusiaev V.Iu. Patogeneticheskoe obosnovanie lechebnogo vozdeistviia na mikrobiotu pri sindrome razdrazhennogo kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (4): 7–14 (in Russian).]
52. Krogius-Kurikka L, Lyra A, Malinen E et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95.
53. Kerckhoffs APM, Samsom M, van der Rest ME et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887–92.
54. Malinen E, Rinttilä T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373–82.
55. Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185–94.
56. Si JM, Yu YC, Fan YJ et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802–5.
57. Шендеров Б.А., Ткаченко Е.И., Лазебник Л.Б. и др. Метабиотики – новая технология профилактики и лечения заболеваний, связанных с микроэкологическими нарушениями в организме человека. Эксперим. и клин. гастроэнтерология. 2018; 151 (3): 83–92.
[Shenderov B.A., Tkachenko E.I., Lazebnik L.B. et al. Metabiotiki – novaia tekhnologiia profilaktiki i lecheniia zabolevanii, sviazannykh s mikroekologicheskimi narusheniiami v organizme cheloveka. Eksperim. i klin. gastroenterologiia. 2018; 151 (3): 83–92 (in Russian).]
58. Ардатская М.Д., Столярова Л.Г., Архипова Е.В., Филимонова О.Ю. Метабиотики как естественное развитие пробиотической концепции. Трудный пациент. 2017; 6–7 (15): 35–9.
[Ardatskaia M.D., Stoliarova L.G., Arkhipova E.V., Filimonova O.Iu. Metabiotiki kak estestvennoe razvitie probioticheskoi kontseptsii. Trudnyi patsient. 2017; 6–7 (15): 35–9 (in Russian).]
59. Ардатская М.Д., Логинов В.А., Минушкин О.Н. Новые возможности диагностики и коррекции микроэкологических нарушений кишечника. Consilium Medicum. Гастроэнтерология. 2013; 2: 51–8.
[Ardatskaia M.D., Loginov V.A., Minushkin O.N. Novye vozmozhnosti diagnostiki i korrektsii mikroekologicheskikh narushenii kishechnika. Consilium Medicum. Gastroenterology. 2013; 2: 51–8 (in Russian).]
60. Павленко В.В., Катаганова Г.А., Александрова С.Б. и др. Пробиотики и воспалительные заболевания кишечника: оценка эффективности пробиотического комплекса «Бактистатин» в терапии больных язвенным колитом. Современные проблемы науки и образования. 2015; 5.
[Pavlenko V.V., Kataganova G.A., Aleksandrova S.B. et al. Probiotiki i vospalitel'nye zabolevaniia kishechnika: otsenka effektivnosti probioticheskogo kompleksa "Baktistatin' v terapii bol'nykh iazvennym kolitom. Sovremennye problemy nauki i obrazovaniia. 2015; 5 (in Russian).]
61. Агафонова Н.А., Яковенко Э.П., Иванов А.Н., Яковенко А.В. Эффективность препарата Бактистатин в лечении постинфекционного синдрома раздраженного кишечника. Лечебное дело. 2017; 3: 54–60.
[Agafonova N.A., Iakovenko E.P., Ivanov A.N., Iakovenko A.V. Effektivnost' preparata Baktistatin v lechenii postinfektsionnogo sindroma razdrazhennogo kishechnika. Lechebnoe delo. 2017; 3: 54–60 (in Russian).]
62. Шкляев А.Е. Улучшение качества жизни больных с синдромом раздраженного кишечника на фоне приема пробиотического комплекса. Consilum Medicum. Гастроэнтерология. 2016; 1: 27–30.
[Shkliaev A.E. Uluchshenie kachestva zhizni bol'nykh s sindromom razdrazhennogo kishechnika na fone priema probioticheskogo kompleksa. Consilum Medicum. Gastroenterology. 2016; 1: 27–30 (in Russian).]
63. Бехтерева М.К., Лукьянова А.М., Хорошева Т.С. и др. Современные подходы к рациональной терапии бактериальных диарей. Лечащий врач. 2014; 12: 54–7.
[Bekhtereva M.K., Luk'ianova A.M., Khorosheva T.S. et al. Sovremennye podkhody k ratsional'noi terapii bakterial'nykh diarei. Lechashchii vrach. 2014; 12: 54–7 (in Russian).]
2. Poluektova E.A., Liashenko O.S., Shifrin O.S. et al. Sovremennye metody izucheniia mikroflory zheludochno-kishechnogo trakta cheloveka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 24 (5): 85–91 (in Russian).
3. Kardymon O.L., Kudriavtseva A.V. Molekuliarno-geneticheskie metody dlia issledovaniia mikrobioma kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 4–13 (in Russian).
4. Kuchumova S.Iu., Poluektova E.A., Sheptulin A.A., Ivashkin V.T. Fiziologicheskoe znachenie kishechnoi mikroflory. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2011; 21 (5): 17–27 (in Russian).
5. Dominguez-Bello MG et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010; 107: 11971–5.
6. Bäckhed F et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015; 17: 690–703.
7. Dominguez-Bello MG et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med 2016; 22: 250–3.
8. Tamburini S, N Shen, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nature Medicine 2016; 22: 713–22.
9. Yatsunenko T et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222–7.
10. Shaw S, Blanchard J, Bernstein C. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2687–92.
11. Barbara G, Stanghellini V, Brandi G et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100: 2560–8.
12. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157: 121–41.
13. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016; 535: 75–84.
14. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016; 16: 341–52.
15. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 2017; 20 (2): 145–55.
16. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735–42.
17. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–12.
18. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015; 17: 565–76.
19. Mukhina A.Iu. Vzaimosviaz' sostoianiia mikrobioty tolstoi kishki i funktsii nervnoi sistemy v usloviiakh immobilizatsionnogo stressa i primeneniia proizvodnogo tafttsina u krys. Avtoref. dis. … kand. med. nauk. K., 2019 (in Russian).
20. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500–12.
21. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306–14.
22. Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From Cytokines to Toll-Like Receptors and Beyond – Current Knowledge and Future Research Needs in Irritable Bowel Syndrome. J Neurogastroenterol Motil 2010; 16 (4): 363–73.
23. Shenderov B.A.Medical microbial ecology and functional nutrition. T. 2. Socio-ecological and clinical consequences of imbalance in the microbial ecology of humans and animals. Moscow: GRANT, 1998 (in Russian).
24. Palmer C, Bik E, DiGiulio D et al. Development of the human infant intestinal microbiota. PloS Biol 2007; 5: e177.
25. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: How do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5: 569–73.
26. Xu J et al. Inaugural Article: Honor thy symbionts. Proc Natl Acad Sci USA 2003; 100: 10452–9.
27. Hooper LV, Wong MH, Thelin A et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881–4.
28. Cherbut C, Aube AC, Blottiere HM, et al. In vitro contractile effects of short chain fatty acids in the rat terminal ileum. Gut 1996; 38: 53–8.
29. Rondeau MP, Meltzer K, Michel KE, et al. Short chain fatty acids stimulate feline colonic smooth muscle contraction. J Feline Med Surg 2003; 5: 167–73.
30. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28 (2): 203–9.
31. Spiller R, Jenkins D, Thornley J et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000; 47: 804–11.
32. Guarino MP, Sessa R, Altomare A et al. Human colonic myogenic dysfunction induced by mucosal lipopolysaccharide translocation and oxidative stress. Dig Liver Dis 2013; 45: 1011–6.
33. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32 (3): 305–15.
34. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010; 16 (9): 1583–97.
35. Shulpekova Yu.O. The gut microbiome as a special organ. Grew up. zhurn. gastroenterology, hepatology, coloproctology. 2014; 24 (6): 82-8 (in Russian).
36. Eamonn M, Quigley M. Microflora Modulation of Motility. J Neurogastroenterol Motil 2011; 17 (2): 140–7.
37. Zhu L, Liu W, Alkhouri R et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics 2014; 46 (18): 679–86.
38. Akin'shina A.I., Smirnova D.V., Zagainova A.V. et al. Perspektivy ispol'zovaniia metodov korrektsii mikrobioty pri terapii vospalitel'nykh zabolevanii kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (2): 12–22 (in Russian).
39. Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology 2017; 152 (2): 327–339.e4.
40. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Nat Acad Sci 2008; 105 (43): 16731–6.
41. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712–21.
42. Ivashkin V.T., Zol'nikova O.Iu. Sindrom razdrazhennogo kishechnika s pozitsii izmenenii mikrobioty. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (1): 84–92 (in Russian).
43. Sheptulin A.A., Vize-Khripunova M.A. Rimskie kriterii sindroma razdrazhennogo kishechnika IV peresmotra: est' li printsipial'nye izmeneniia? Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (5): 99–103 (in Russian).
44. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016; 19.
45. Thabane M, Kottachchi DT, Marshall JK. Systematic review and metaanalysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535–44.
46. Villarreal AA, Aberger FJ, Benrud R et al. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17–20.
47. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205–15.
48. Jeffery IB, O’Toole PW, Öhman L et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997–1006.
49. Rajilić-Stojanović M, Biagi E, Heilig HGHJ et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–801.
50. Jalanka-Tuovinen J, Salojärvi J, Salonen A et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014; 63: 1737–45.
51. Shul'pekova Iu.O., Babaeva G.G., Rusiaev V.Iu. Patogeneticheskoe obosnovanie lechebnogo vozdeistviia na mikrobiotu pri sindrome razdrazhennogo kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (4): 7–14 (in Russian).
52. Krogius-Kurikka L, Lyra A, Malinen E et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95.
53. Kerckhoffs APM, Samsom M, van der Rest ME et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887–92.
54. Malinen E, Rinttilä T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373–82.
55. Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185–94.
56. Si JM, Yu YC, Fan YJ et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802–5.
57. Shenderov B.A., Tkachenko E.I., Lazebnik L.B. et al. Metabiotiki – novaia tekhnologiia profilaktiki i lecheniia zabolevanii, sviazannykh s mikroekologicheskimi narusheniiami v organizme cheloveka. Eksperim. i klin. gastroenterologiia. 2018; 151 (3): 83–92 (in Russian).
58. Ardatskaia M.D., Stoliarova L.G., Arkhipova E.V., Filimonova O.Iu. Metabiotiki kak estestvennoe razvitie probioticheskoi kontseptsii. Trudnyi patsient. 2017; 6–7 (15): 35–9 (in Russian).
59. Ardatskaia M.D., Loginov V.A., Minushkin O.N. Novye vozmozhnosti diagnostiki i korrektsii mikroekologicheskikh narushenii kishechnika. Consilium Medicum. Gastroenterology. 2013; 2: 51–8 (in Russian).
60. Pavlenko V.V., Kataganova G.A., Aleksandrova S.B. et al. Probiotiki i vospalitel'nye zabolevaniia kishechnika: otsenka effektivnosti probioticheskogo kompleksa "Baktistatin' v terapii bol'nykh iazvennym kolitom. Sovremennye problemy nauki i obrazovaniia. 2015; 5 (in Russian).
61. Agafonova N.A., Iakovenko E.P., Ivanov A.N., Iakovenko A.V. Effektivnost' preparata Baktistatin v lechenii postinfektsionnogo sindroma razdrazhennogo kishechnika. Lechebnoe delo. 2017; 3: 54–60 (in Russian).
62. Shkliaev A.E. Uluchshenie kachestva zhizni bol'nykh s sindromom razdrazhennogo kishechnika na fone priema probioticheskogo kompleksa. Consilum Medicum. Gastroenterology. 2016; 1: 27–30 (in Russian).
63. Bekhtereva M.K., Luk'ianova A.M., Khorosheva T.S. et al. Sovremennye podkhody k ratsional'noi terapii bakterial'nykh diarei. Lechashchii vrach. 2014; 12: 54–7 (in Russian).
2. Полуэктова Е.А., Ляшенко О.С., Шифрин О.С. и др. Современные методы изучения микрофлоры желудочно-кишечного тракта человека. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 24 (5): 85–91.
[Poluektova E.A., Liashenko O.S., Shifrin O.S. et al. Sovremennye metody izucheniia mikroflory zheludochno-kishechnogo trakta cheloveka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 24 (5): 85–91 (in Russian).]
3. Кардымон О.Л., Кудрявцева А.В. Молекулярно-генетические методы для исследования микробиома кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (4): 4–13.
[Kardymon O.L., Kudriavtseva A.V. Molekuliarno-geneticheskie metody dlia issledovaniia mikrobioma kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 4–13 (in Russian).]
4. Кучумова С.Ю., Полуэктова Е.А., Шептулин А.А., Ивашкин В.Т. Физиологическое значение кишечной микрофлоры. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2011; 21 (5): 17–27.
[Kuchumova S.Iu., Poluektova E.A., Sheptulin A.A., Ivashkin V.T. Fiziologicheskoe znachenie kishechnoi mikroflory. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2011; 21 (5): 17–27 (in Russian).]
5. Dominguez-Bello MG et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010; 107: 11971–5.
6. Bäckhed F et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015; 17: 690–703.
7. Dominguez-Bello MG et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med 2016; 22: 250–3.
8. Tamburini S, N Shen, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nature Medicine 2016; 22: 713–22.
9. Yatsunenko T et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222–7.
10. Shaw S, Blanchard J, Bernstein C. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2687–92.
11. Barbara G, Stanghellini V, Brandi G et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100: 2560–8.
12. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157: 121–41.
13. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016; 535: 75–84.
14. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016; 16: 341–52.
15. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 2017; 20 (2): 145–55.
16. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735–42.
17. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–12.
18. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015; 17: 565–76.
19. Мухина А.Ю. Взаимосвязь состояния микробиоты толстой кишки и функций нервной системы в условиях иммобилизационного стресса и применения производного тафтцина у крыс. Автореф. дис. … канд. мед. наук. К., 2019.
[Mukhina A.Iu. Vzaimosviaz' sostoianiia mikrobioty tolstoi kishki i funktsii nervnoi sistemy v usloviiakh immobilizatsionnogo stressa i primeneniia proizvodnogo tafttsina u krys. Avtoref. dis. … kand. med. nauk. K., 2019 (in Russian).]
20. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500–12.
21. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306–14.
22. Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From Cytokines to Toll-Like Receptors and Beyond – Current Knowledge and Future Research Needs in Irritable Bowel Syndrome. J Neurogastroenterol Motil 2010; 16 (4): 363–73.
23. Шендеров Б. А. Медицинская микробная экология и функциональное питание. Т. 2. Социально-экологические и клинические последствия дисбаланса микробной экологии человека и животных. М.: ГРАНТЪ, 1998.
[Shenderov B.A.Medical microbial ecology and functional nutrition. T. 2. Socio-ecological and clinical consequences of imbalance in the microbial ecology of humans and animals. Moscow: GRANT, 1998 (in Russian).]
24. Palmer C, Bik E, DiGiulio D et al. Development of the human infant intestinal microbiota. PloS Biol 2007; 5: e177.
25. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: How do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5: 569–73.
26. Xu J et al. Inaugural Article: Honor thy symbionts. Proc Natl Acad Sci USA 2003; 100: 10452–9.
27. Hooper LV, Wong MH, Thelin A et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881–4.
28. Cherbut C, Aube AC, Blottiere HM, et al. In vitro contractile effects of short chain fatty acids in the rat terminal ileum. Gut 1996; 38: 53–8.
29. Rondeau MP, Meltzer K, Michel KE, et al. Short chain fatty acids stimulate feline colonic smooth muscle contraction. J Feline Med Surg 2003; 5: 167–73.
30. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28 (2): 203–9.
31. Spiller R, Jenkins D, Thornley J et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000; 47: 804–11.
32. Guarino MP, Sessa R, Altomare A et al. Human colonic myogenic dysfunction induced by mucosal lipopolysaccharide translocation and oxidative stress. Dig Liver Dis 2013; 45: 1011–6.
33. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32 (3): 305–15.
34. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010; 16 (9): 1583–97.
35. Шульпекова Ю.О. Кишечный микробиом как особый орган. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 24 (6): 82–8.
[Shulpekova Yu.O. The gut microbiome as a special organ. Grew up. zhurn. gastroenterology, hepatology, coloproctology. 2014; 24 (6): 82-8 (in Russian).]
36. Eamonn M, Quigley M. Microflora Modulation of Motility. J Neurogastroenterol Motil 2011; 17 (2): 140–7.
37. Zhu L, Liu W, Alkhouri R et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics 2014; 46 (18): 679–86.
38. Акиньшина А.И., Смирнова Д.В., Загайнова А.В. и др. Перспективы использования методов коррекции микробиоты при терапии воспалительных заболеваний кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (2): 12–22.
[Akin'shina A.I., Smirnova D.V., Zagainova A.V. et al. Perspektivy ispol'zovaniia metodov korrektsii mikrobioty pri terapii vospalitel'nykh zabolevanii kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (2): 12–22 (in Russian).]
39. Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology 2017; 152 (2): 327–339.e4.
40. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Nat Acad Sci 2008; 105 (43): 16731–6.
41. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712–21.
42. Ивашкин В.Т., Зольникова О.Ю. Синдром раздраженного кишечника с позиций изменений микробиоты. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (1): 84–92.
[Ivashkin V.T., Zol'nikova O.Iu. Sindrom razdrazhennogo kishechnika s pozitsii izmenenii mikrobioty. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (1): 84–92 (in Russian).]
43. Шептулин А.А., Визе-Хрипунова М.А. Римские критерии синдрома раздраженного кишечника IV пересмотра: есть ли принципиальные изменения? Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (5): 99–103.
[Sheptulin A.A., Vize-Khripunova M.A. Rimskie kriterii sindroma razdrazhennogo kishechnika IV peresmotra: est' li printsipial'nye izmeneniia? Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (5): 99–103 (in Russian).]
44. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016; 19.
45. Thabane M, Kottachchi DT, Marshall JK. Systematic review and metaanalysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535–44.
46. Villarreal AA, Aberger FJ, Benrud R et al. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17–20.
47. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205–15.
48. Jeffery IB, O’Toole PW, Öhman L et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997–1006.
49. Rajilić-Stojanović M, Biagi E, Heilig HGHJ et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–801.
50. Jalanka-Tuovinen J, Salojärvi J, Salonen A et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014; 63: 1737–45.
51. Шульпекова Ю.О., Бабаева Г.Г., Русяев В.Ю. Патогенетическое обоснование лечебного воздействия на микробиоту при синдроме раздраженного кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (4): 7–14.
[Shul'pekova Iu.O., Babaeva G.G., Rusiaev V.Iu. Patogeneticheskoe obosnovanie lechebnogo vozdeistviia na mikrobiotu pri sindrome razdrazhennogo kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (4): 7–14 (in Russian).]
52. Krogius-Kurikka L, Lyra A, Malinen E et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95.
53. Kerckhoffs APM, Samsom M, van der Rest ME et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887–92.
54. Malinen E, Rinttilä T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373–82.
55. Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185–94.
56. Si JM, Yu YC, Fan YJ et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802–5.
57. Шендеров Б.А., Ткаченко Е.И., Лазебник Л.Б. и др. Метабиотики – новая технология профилактики и лечения заболеваний, связанных с микроэкологическими нарушениями в организме человека. Эксперим. и клин. гастроэнтерология. 2018; 151 (3): 83–92.
[Shenderov B.A., Tkachenko E.I., Lazebnik L.B. et al. Metabiotiki – novaia tekhnologiia profilaktiki i lecheniia zabolevanii, sviazannykh s mikroekologicheskimi narusheniiami v organizme cheloveka. Eksperim. i klin. gastroenterologiia. 2018; 151 (3): 83–92 (in Russian).]
58. Ардатская М.Д., Столярова Л.Г., Архипова Е.В., Филимонова О.Ю. Метабиотики как естественное развитие пробиотической концепции. Трудный пациент. 2017; 6–7 (15): 35–9.
[Ardatskaia M.D., Stoliarova L.G., Arkhipova E.V., Filimonova O.Iu. Metabiotiki kak estestvennoe razvitie probioticheskoi kontseptsii. Trudnyi patsient. 2017; 6–7 (15): 35–9 (in Russian).]
59. Ардатская М.Д., Логинов В.А., Минушкин О.Н. Новые возможности диагностики и коррекции микроэкологических нарушений кишечника. Consilium Medicum. Гастроэнтерология. 2013; 2: 51–8.
[Ardatskaia M.D., Loginov V.A., Minushkin O.N. Novye vozmozhnosti diagnostiki i korrektsii mikroekologicheskikh narushenii kishechnika. Consilium Medicum. Gastroenterology. 2013; 2: 51–8 (in Russian).]
60. Павленко В.В., Катаганова Г.А., Александрова С.Б. и др. Пробиотики и воспалительные заболевания кишечника: оценка эффективности пробиотического комплекса «Бактистатин» в терапии больных язвенным колитом. Современные проблемы науки и образования. 2015; 5.
[Pavlenko V.V., Kataganova G.A., Aleksandrova S.B. et al. Probiotiki i vospalitel'nye zabolevaniia kishechnika: otsenka effektivnosti probioticheskogo kompleksa "Baktistatin' v terapii bol'nykh iazvennym kolitom. Sovremennye problemy nauki i obrazovaniia. 2015; 5 (in Russian).]
61. Агафонова Н.А., Яковенко Э.П., Иванов А.Н., Яковенко А.В. Эффективность препарата Бактистатин в лечении постинфекционного синдрома раздраженного кишечника. Лечебное дело. 2017; 3: 54–60.
[Agafonova N.A., Iakovenko E.P., Ivanov A.N., Iakovenko A.V. Effektivnost' preparata Baktistatin v lechenii postinfektsionnogo sindroma razdrazhennogo kishechnika. Lechebnoe delo. 2017; 3: 54–60 (in Russian).]
62. Шкляев А.Е. Улучшение качества жизни больных с синдромом раздраженного кишечника на фоне приема пробиотического комплекса. Consilum Medicum. Гастроэнтерология. 2016; 1: 27–30.
[Shkliaev A.E. Uluchshenie kachestva zhizni bol'nykh s sindromom razdrazhennogo kishechnika na fone priema probioticheskogo kompleksa. Consilum Medicum. Gastroenterology. 2016; 1: 27–30 (in Russian).]
63. Бехтерева М.К., Лукьянова А.М., Хорошева Т.С. и др. Современные подходы к рациональной терапии бактериальных диарей. Лечащий врач. 2014; 12: 54–7.
[Bekhtereva M.K., Luk'ianova A.M., Khorosheva T.S. et al. Sovremennye podkhody k ratsional'noi terapii bakterial'nykh diarei. Lechashchii vrach. 2014; 12: 54–7 (in Russian).]
________________________________________________
2. Poluektova E.A., Liashenko O.S., Shifrin O.S. et al. Sovremennye metody izucheniia mikroflory zheludochno-kishechnogo trakta cheloveka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 24 (5): 85–91 (in Russian).
3. Kardymon O.L., Kudriavtseva A.V. Molekuliarno-geneticheskie metody dlia issledovaniia mikrobioma kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 4–13 (in Russian).
4. Kuchumova S.Iu., Poluektova E.A., Sheptulin A.A., Ivashkin V.T. Fiziologicheskoe znachenie kishechnoi mikroflory. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2011; 21 (5): 17–27 (in Russian).
5. Dominguez-Bello MG et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010; 107: 11971–5.
6. Bäckhed F et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015; 17: 690–703.
7. Dominguez-Bello MG et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med 2016; 22: 250–3.
8. Tamburini S, N Shen, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nature Medicine 2016; 22: 713–22.
9. Yatsunenko T et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222–7.
10. Shaw S, Blanchard J, Bernstein C. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2687–92.
11. Barbara G, Stanghellini V, Brandi G et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100: 2560–8.
12. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157: 121–41.
13. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016; 535: 75–84.
14. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016; 16: 341–52.
15. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 2017; 20 (2): 145–55.
16. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735–42.
17. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–12.
18. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015; 17: 565–76.
19. Mukhina A.Iu. Vzaimosviaz' sostoianiia mikrobioty tolstoi kishki i funktsii nervnoi sistemy v usloviiakh immobilizatsionnogo stressa i primeneniia proizvodnogo tafttsina u krys. Avtoref. dis. … kand. med. nauk. K., 2019 (in Russian).
20. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500–12.
21. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306–14.
22. Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From Cytokines to Toll-Like Receptors and Beyond – Current Knowledge and Future Research Needs in Irritable Bowel Syndrome. J Neurogastroenterol Motil 2010; 16 (4): 363–73.
23. Shenderov B.A.Medical microbial ecology and functional nutrition. T. 2. Socio-ecological and clinical consequences of imbalance in the microbial ecology of humans and animals. Moscow: GRANT, 1998 (in Russian).
24. Palmer C, Bik E, DiGiulio D et al. Development of the human infant intestinal microbiota. PloS Biol 2007; 5: e177.
25. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: How do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5: 569–73.
26. Xu J et al. Inaugural Article: Honor thy symbionts. Proc Natl Acad Sci USA 2003; 100: 10452–9.
27. Hooper LV, Wong MH, Thelin A et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881–4.
28. Cherbut C, Aube AC, Blottiere HM, et al. In vitro contractile effects of short chain fatty acids in the rat terminal ileum. Gut 1996; 38: 53–8.
29. Rondeau MP, Meltzer K, Michel KE, et al. Short chain fatty acids stimulate feline colonic smooth muscle contraction. J Feline Med Surg 2003; 5: 167–73.
30. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28 (2): 203–9.
31. Spiller R, Jenkins D, Thornley J et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000; 47: 804–11.
32. Guarino MP, Sessa R, Altomare A et al. Human colonic myogenic dysfunction induced by mucosal lipopolysaccharide translocation and oxidative stress. Dig Liver Dis 2013; 45: 1011–6.
33. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32 (3): 305–15.
34. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010; 16 (9): 1583–97.
35. Shulpekova Yu.O. The gut microbiome as a special organ. Grew up. zhurn. gastroenterology, hepatology, coloproctology. 2014; 24 (6): 82-8 (in Russian).
36. Eamonn M, Quigley M. Microflora Modulation of Motility. J Neurogastroenterol Motil 2011; 17 (2): 140–7.
37. Zhu L, Liu W, Alkhouri R et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics 2014; 46 (18): 679–86.
38. Akin'shina A.I., Smirnova D.V., Zagainova A.V. et al. Perspektivy ispol'zovaniia metodov korrektsii mikrobioty pri terapii vospalitel'nykh zabolevanii kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (2): 12–22 (in Russian).
39. Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology 2017; 152 (2): 327–339.e4.
40. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Nat Acad Sci 2008; 105 (43): 16731–6.
41. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712–21.
42. Ivashkin V.T., Zol'nikova O.Iu. Sindrom razdrazhennogo kishechnika s pozitsii izmenenii mikrobioty. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (1): 84–92 (in Russian).
43. Sheptulin A.A., Vize-Khripunova M.A. Rimskie kriterii sindroma razdrazhennogo kishechnika IV peresmotra: est' li printsipial'nye izmeneniia? Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (5): 99–103 (in Russian).
44. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016; 19.
45. Thabane M, Kottachchi DT, Marshall JK. Systematic review and metaanalysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535–44.
46. Villarreal AA, Aberger FJ, Benrud R et al. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17–20.
47. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205–15.
48. Jeffery IB, O’Toole PW, Öhman L et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997–1006.
49. Rajilić-Stojanović M, Biagi E, Heilig HGHJ et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–801.
50. Jalanka-Tuovinen J, Salojärvi J, Salonen A et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014; 63: 1737–45.
51. Shul'pekova Iu.O., Babaeva G.G., Rusiaev V.Iu. Patogeneticheskoe obosnovanie lechebnogo vozdeistviia na mikrobiotu pri sindrome razdrazhennogo kishechnika. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (4): 7–14 (in Russian).
52. Krogius-Kurikka L, Lyra A, Malinen E et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95.
53. Kerckhoffs APM, Samsom M, van der Rest ME et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887–92.
54. Malinen E, Rinttilä T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373–82.
55. Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185–94.
56. Si JM, Yu YC, Fan YJ et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802–5.
57. Shenderov B.A., Tkachenko E.I., Lazebnik L.B. et al. Metabiotiki – novaia tekhnologiia profilaktiki i lecheniia zabolevanii, sviazannykh s mikroekologicheskimi narusheniiami v organizme cheloveka. Eksperim. i klin. gastroenterologiia. 2018; 151 (3): 83–92 (in Russian).
58. Ardatskaia M.D., Stoliarova L.G., Arkhipova E.V., Filimonova O.Iu. Metabiotiki kak estestvennoe razvitie probioticheskoi kontseptsii. Trudnyi patsient. 2017; 6–7 (15): 35–9 (in Russian).
59. Ardatskaia M.D., Loginov V.A., Minushkin O.N. Novye vozmozhnosti diagnostiki i korrektsii mikroekologicheskikh narushenii kishechnika. Consilium Medicum. Gastroenterology. 2013; 2: 51–8 (in Russian).
60. Pavlenko V.V., Kataganova G.A., Aleksandrova S.B. et al. Probiotiki i vospalitel'nye zabolevaniia kishechnika: otsenka effektivnosti probioticheskogo kompleksa "Baktistatin' v terapii bol'nykh iazvennym kolitom. Sovremennye problemy nauki i obrazovaniia. 2015; 5 (in Russian).
61. Agafonova N.A., Iakovenko E.P., Ivanov A.N., Iakovenko A.V. Effektivnost' preparata Baktistatin v lechenii postinfektsionnogo sindroma razdrazhennogo kishechnika. Lechebnoe delo. 2017; 3: 54–60 (in Russian).
62. Shkliaev A.E. Uluchshenie kachestva zhizni bol'nykh s sindromom razdrazhennogo kishechnika na fone priema probioticheskogo kompleksa. Consilum Medicum. Gastroenterology. 2016; 1: 27–30 (in Russian).
63. Bekhtereva M.K., Luk'ianova A.M., Khorosheva T.S. et al. Sovremennye podkhody k ratsional'noi terapii bakterial'nykh diarei. Lechashchii vrach. 2014; 12: 54–7 (in Russian).
Авторы
А.С. Трухманов*, Д.Е. Румянцева
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*troukh@mail.ru
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*troukh@mail.ru
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*troukh@mail.ru
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*troukh@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.